• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutic (NQ: ONTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Onconova Therapeutic

< Previous 1 2 Next >
Traws Pharma Announces New Employee Inducement Grants
April 02, 2024
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 02, 2024
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 08, 2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 12, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 28, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 14, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 07, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
November 02, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Expands Leadership Team with Two Key Appointments
October 24, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
October 19, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Encouraging Rigosertib Data Presented at EADV as Late Breaker
October 12, 2023
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
September 28, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
August 10, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
June 14, 2023
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
May 25, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
May 12, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
May 11, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
May 08, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
May 04, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
April 19, 2023
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitors 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
April 06, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
March 23, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
March 15, 2023
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
March 09, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap